Search

for
Search:

GlossaryImatinib (Gleevec)

targets specific enzymes to treat certain cancers like CML

Imatinib, also known as Gleevec, is a targeted cancer therapy drug used primarily to treat chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs). It works by inhibiting specific tyrosine kinases, which are enzymes that promote the growth of cancer cells, thereby slowing or stopping the progression of the disease.

Related Terms

Learn

0 / 0 results

— no results

Research

5 / 29 results

research Author Reply

1 citations, April 2004 in “Cancer”

Imatinib mesylate can cause skin lightening, especially in Chinese patients, due to its effect on pigment production.

research Tyrosine Kinase Inhibitors: A Review on Pharmacology, Metabolism, and Side Effects

508 citations, June 2009 in “Current drug metabolism”

Tyrosine kinase inhibitors effectively treat cancers but often cause skin and other side effects.

research Tumor Regression Predicts Higher Risk of Sentinel Node Involvement in Thin Cutaneous Melanomas

68 citations, September 2003 in “British Journal of Dermatology”

Shrinking skin cancer increases the chance of cancer in nearby lymph nodes.

research Imatinib-Induced Classical Lichen Planopilaris in Blaschko-Linear Distribution Leading to Cicatricial Alopecia

2 citations, January 2021 in “Indian Dermatology Online Journal”

Imatinib can cause hair loss due to lichen planopilaris.

research Skin Manifestations of Chronic Kidney Disease

September 2015 in “Actas Dermo-Sifiliográficas”

People with advanced chronic kidney disease often have skin problems, which can be treated with various medications and procedures to improve their quality of life.

View more "gleevec" in research →

Community Join

0 / 0 results

— no results